Shares of Novartis fell more than 3% on Monday after its cholesterol drug failed in a closely watched study, dealing ‌a blow ...

Like LDL-cholesterol, elevated Lp (a) is recognised as an independent genetic risk factor for coronary artery disease, heart ...

Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a phase 3 trial ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Sept 4 (Reuters) - Ionis Pharmaceuticals and partner Novartis' experimental drug to lower high levels of a ...

By Bhanvi Satija LONDON, Sept 1 (Reuters) - Swiss drugmaker Novartis said on Tuesday its oral drug remibrutinib outperformed ...

NOVARTIS NOVN.S said on Friday its experimental drug pelacarsen did not cut the risk of major heart attacks and strokes in patients with a genetic risk factor in a late-stage trial, marking a setback ...

The oral drug remibrutinib cut relapse rates in patients with relapsing multiple sclerosis, beating a rival treatment in both ...

The halt was implemented on August 24 after Novartis was notified of three cases of a severe, life-threatening immune ...

The win marks a milestone, given previous terminations in this drug class from AstraZeneca and Eli Lilly.

Bengaluru: Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders ...

Novartis shares rose after the drugmaker reported positive results in two late-stage trials from its new pill for the most common form of multiple sclerosis.